Condition: Myelofibrosis · Sponsor: Cellenkos, Inc.
To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib
This description comes directly from the study's public registry record.
Tara Sadeghi · 713-806-4787 · tara.sadeghi@cellenkosinc.com
Stacy Minor · 832-962-7628 · stacy.minor@cellenkosinc.com
Always discuss trial participation with your own doctor first.
| UC Davis Health | Sacramento, California, United States | Recruiting |
| Columbia University | New York, New York, United States | Not Yet Recruiting |
| Montefiore Einstein Cancer Center | The Bronx, New York, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05423691